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Background: V-betaLH is a common genetic variant of LH caused by two polymorphic base changes in the beta
subunit gene, altering the amino acid sequence (Trp8Arg and Ile15Thr). In a previous-preliminary trial performed in
women undergoing IVF, it was demonstrated that carriers of v-betaLH show sub-optimal ovarian response to a
standard long GnRH-agonist down -regulation protocol when stimulated with pure recombinant FSH (r-hFSH). The
aim of this study was to confirm the hypothesis that women with v-betaLH display hypo-sensitivity to exogenous
FSH in a larger IVF population and to explore the frequency of this variant in a Danish female population.
Methods: In the present study, the effect of v-betaLH was retrospectively investigated in a larger series of women
undergoing controlled ovarian stimulation (COS) and, for the first time, in a Danish IVF population. A total of 220
normogonadotrophic women following a long GnRH-agonist down-regulation protocol received an individualized
dose of r-hFSH (100 IU and 375 IU s.c. daily) according to antral follicle count, baseline FSH, body mass index and
age. The LH genotype was assessed in all patients by immunofluorometric assay.
Results: V-betaLH was present in 11% of patients, whereas the allelic frequency was 12%. The study population
was divided into two groups according to their LH genotype. Group A consisted of 196 wt/wt women. Group B
included 24 individuals with v-betaLH (21 heterozygous and 3 homozygous). No statistically significant
differences in the mean number of oocytes retrieved, fertilization rate and pregnancy rate per cycle were
observed between groups. However, Group B received a significantly higher cumulative-dose of r-hFSH than
Group A (2435.86 +/− 932.8 IU versus 1959.8 +/− 736.45 p = 0.048). When one-way ANOVA in a within design
was applied, the LH genotype had a statistically significant effect (p < 0.01) on the cumulative dose of r-hFSH,
showing a progressive increase from wt/wt (1959.8 +/− 736.45 IU) to v-betaLH hetero- (2267.5 +/− 824.3) and
homozygotic women (3558.3 +/− 970.9).
Conclusions: These results confirm that carriers exhibit hypo-sensitivity to exogenous FSH during COS, documenting
that the frequency of v-betaLH in Denmark is similar to a number of European countries.
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Table 1 The carrier frequencies of v-beta LH common
variant in different ethnic groups
Population Sample
(n)
Frequency
(%)
95% Confidence
interval
Finland (Lapps) 129 41.9 33.4 - 50.4
Sweden 376 18.9 14.9 - 22.9
United Kingdom 212 15.1 10.3- 19.9
Italy 294 13.9 9.7 - 26.4
United States (black) 251 14.7 10.3 - 19.1
United States
(hispanic)
196 7.1 3.5 - 10.7
From Nilsson et al. [17], (modified).
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More than 80% of patients receiving stimulation with
exogenous follicle-stimulating hormone (FSH), devoid of
any luteinizing hormone (LH) activity during IVF/ICSI,
respond adequately to the stimulation in terms of fol-
licular development and steroid synthesis. However,
approximately 10% of patients require a higher dose of
recombinant human FSH (r-hFSH) to obtain an optimal
response. This subgroup of patients was recently classi-
fied as hypo-responder patients [1-5]. In contrast to the
classical poor-responder, this type of patient possesses a
normal ovarian reserve and follicular recruitment, how-
ever, requires more r-hFSH than a normal-responder
patient during controlled ovarian stimulation (COS).
Although the attenuated response of the hypo-responder
patient has not yet been identified, recent data suggest a
possible role of LH. Firstly, it was demonstrated that sup-
plementation with exogenous LH could be a useful stra-
tegy to improve ovarian response in this type of patient
[2-4]. Thus, the use of recombinant human LH (r-hLH)
supplementation during stimulation normalized the ovar-
ian response and decreased the r-hFSH consumption [6].
Interestingly, the base line endogenous LH levels in these
patients were similar to normal responding women, and it
was postulated that different bioactive form of LH, known
as v-betaLH, could characterize this type of patient; a
hypothesis which was recently supported in a study by
Alviggi et al. [7].
LH plays a key role in gonadal function by regulating
the production of androgens, the precursor molecules of
estrogens in theca cells. Although LH-receptors are
expressed on human follicles already from the start of
the cycle [8], the synergizing effect of LH and FSH ap-
pears to be most prominent from the mid-follicular
phase and onwards. LH is a heterodimeric hormone
characterized by two subunits, alfa and beta, produced
in the anterior pituitary gland; the beta-subunit confers
the specificity of the hormone. However, different types
of LH with different biological and pharmacokinetic fea-
tures have been identified. Thus, there are four genetic
variant types of the beta-subunit of LH. The first type
was discovered in 1992 when Weiss et al. reported a
case of a young man affected by pubertal retardation [9].
The basal LH level in this patient was twice the normal
level, however, obviously of a poor biological activity due
to a substitution of a glycine to arginine in the 54th pos-
ition. During a study testing new monoclonal antibodies
for LH measurement, another anomalous LH form was
discovered [10]. The altered immune-reactivity was caused
by a Trp8Arg mutation [11]. This variant (v-betaLH)
seems to be significantly widespread in different ethnical
groups (Table 1). Thus, the carrier frequency in Finland
has been reported to be as high as 41.9%, while a signifi-
cantly lower incidence was detected in Bengali inhabitants(about 2.56%). In Italy, the carrier frequency of this poly-
morphic variant is approximately 14%.
Importantly, the v-betaLH is characterized by an extra
glycosylation signal into the β subunit, which apparently
adds a second oligosaccharide side-chain to Asn13 of
the β protein. This molecular variation influences the
pharmacokinetic properties of v-betaLH which shows an
elevated bioactivity in vitro, but a significantly shorter
half-life (26 min) in circulation when compared with the
wild type LH (48 min) [12]. The aim of the present
study was to corroborate previous findings indicating
higher consumption of exogenous FSH in women with
variant v-betaLH and to explore its frequency in a Danish
female population.Methods
This is a retrospective analysis of the association be-
tween LH polymorphism and the outcome of COS and
IVF. More specifically, samples examined in the present
study were derived from a previously published trial
[13], focusing on ovarian response in relation to mid-
follicular serum LH levels. In that study, a total of 220
Danish women undergoing IVF or ICSI treatment in the
Fertility Clinic at Skive regional hospital (Skive,
Denmark) were prospectively enrolled in a consecutive
manner. Exclusion criteria were: age > 40 years and base-
line FSH >10 IU/L, any endocrine, genetic, systemic
inflammatory-immunological disorder, polycystic ovarian
syndrome, endometriosis and presence of one ovary,
only. A frozen thawed serum sample from all patients
was used to evaluate the presence of v-betaLH.
An Institutional Review Board approval was not re-
quired for the present study, as frozen serum samples
derived from a previous study, approved by The Ethics
Committee of Viborg County, during which each pa-
tient had given written consent [13]. Moreover, data was
managed in a manner which excluded the identification
of subjects.
Table 2 Characteristics and infertility diagnosis of wild
type and carriers of v-betaLH
Group A
wild-type
n = 196
Group B
v-betaLH v
n = 24
p-value
A vs B
Age (yrs)* 30.8 ± 4.0 30.5 ± 3.9 NS
BMI (Kg/m2)* 24.8 ± 3.1 25.3 ± 3.4 NS
Basal E2 (nmol/L)* 0.4 ± 0.9 0.2 ± 0.15 NS
Basal FSH (UI/L)* 6.2 ± 1.8 6.7 ± 1.35 NS
Basal LH (UI/L)* 5.7 ± 2.7 5.4 ± 2.5 NS
Infertility diagnosis
Tubal factor (%) 26.5 16.75 NS
Male factor (%) 32.7 29.15 NS
Idiopathic form (%) 16.3 16.75 NS
Combined (%) 16.3 29.15 NS
Other (%) 8.7 8.2 NS
*Values are reported as mean ± SD.
Abbreviation: NS not statistically significant.
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All patients underwent a long gonadotropin-releasing hor-
mone agonist (GnRH-a) down-regulation protocol as pre-
viously described [13]. In brief, pituitary desensitization
was induced by the administration of GnRH-a (Suprefact;
Hoechst, Horsholm, Denmark) 0.8 mg s.c. daily from the
mid-luteal phase for 12–20 days, followed by a reduc-
tion of GnRH-a to 0.4 mg s.c. daily. Ovarian stimulation
was performed with r-hFSH (Gonal F; Serono Nordic,
Copenhagen, Denmark or Puregon; MSD, Ballerup,
Denmark), using an individualized dose between 100 IU
and 375 IU s.c. daily according to antral follicle count,
baseline FSH, body mass index (BMI) and age. The ova-
rian response was monitored by ultrasound examination
starting on day 8 of stimulation and the dose of r-hFSH
was adjusted if necessary. The ovulatory dose of human
chorionic gonadotropin (hCG), 10.000 IU (Profasi; Serono
Nordic, Copenhagen, Denmark) was administered when
at least three follicles reached a mean diameter of 17 mm.
Luteal phase support was given in the form of micronized
progesterone (Cyclogest; Hoechst, Copenhagen, Denmark)
twice daily or once daily (Crinone 8%; Serono Nordic,
Copenhagen, Denmark), starting on the day following
oocyte retrieval and continuing until the day of the preg-
nancy test (i.e. day 12 after embryo transfer). Oocytes were
retrieved 35 h after the hCG injection.
Blood samples and hormone assays
Blood sampling was performed: on stimulation day 1 (S1),
day 8 (S8) on the day of triggering final oocyte maturation,
and on the ovum pick-up (OPU) day. Aliquots were fro-
zen at −20°C for subsequent analysis of estradiol, FSH, LH
and androstendione. LH and FSH were measured by time-
resolved immunofluorometric assay, the AutoDelfia spec.
kit (Wallac Oy, Turku, Finland). Estradiol and androstene-
dione were measured according to manufacturers instruc-
tions using a commercially available RIA kit intended for
measurements in serum (DSL-4200; Diagnostic System
Laboratories, Texas, USA). All assays were intended for
measurements in serum samples.
The hormone assays were carried out at the Fertility
Clinic in Skive Regional Hospital (Skive, Denmark).
V-betaLH Immunofluorometric assay
The venous blood (10 ml) was allowed to clot and
centrifuged at 400 g for 10 min, where after serum was
separated, divided into a maximum of four aliquots and
frozen [13]. After thawing, the LH concentrations of all
serum samples collected were determined by two dif-
ferent immunofluorescent assay (IFMA) as previously
reported [14,15]. In brief, the total LH concentration
was determined using LHspec (Wallac Oy, Turku,
Finland) as this assay also recognizes v-betaLH [10]. The
other assay, I3/A2, recognizes only the wild-type form(wt-LH) of LH. The I3/A2 assay was directly performed
by one of the authors (K.P.) according to the protocol
he previously developed and described [15]. A ratio of
the two assays (wt-LHI3/A2 /total LHLHspec) was used to
determine the LH status of these individuals. Previous
studies have shown that heterozygotes for v-betaLH
have a wt/total LH ratio between 0.2 and 0.9 as the I3/
A2 assay recognizes only about half of the total
immune-reactive LH in heterozygote serum. The ratio
is >0.9 for wt-LH homozygotes and <0.2 for homozy-
gous variants [16].
Statistical analysis
The results are reported as the mean ± SD. Data were
analyzed with the SPSS version 12.0 (SPSS Inc., USA).
An ANOVA one-way model was used to compare con-
tinuous variables; χ2 statistics were used to compare
discontinuous data. Receiving operating characteristics
(ROC) curves were designed to find the best “cumulative
dose” of r-hFSH, predictive of the highest probability to
express V-betaLH variant. A p value <0.05 was consi-
dered statistically significant.
Results
A total of 220 IVF cycles were retrospectively evaluated.
V-betaLH was observed in 10.9% of patients, with an al-
lelic frequency of 12.2%. Patients were divided into two
groups according to LH genotype. Group A consisted
of 196 wt/wt women. Group B included 24 carriers of
v-betaLH in (21 heterozygotic and 3 in homozygotic car-
riers). The two groups were comparable regarding age,
BMI, cause of infertility and indication for IVF. Basal
levels of FSH, LH and estradiol were also similar
(Table 2). The outcome of the two groups is reported in
Table 3 Ovarian response to stimulation and outcome of
IVF treatment according to LH genotype
Group
Awild-type LH
n = 196
Group
Bv-betaLH
n= 24
p value
A vs B
Estradiol Day S1 (nmol/L) 0.1 ± 0.1 0.1 ± 0.1 NS
Estradiol Day S8 (nmol/L) 3.9 ± 2.8 3.4 ± 3.0 NS
Androstenedione on
Day of trigger (ng/mL)
1.5 ± 0.8 2.1 ± 1.3 0.012
Androstenedione on
OPU (ng/mL)
5.35 ± 2.4 5.53 ± 2.3 NS
LH (IU/L) Day S1 1.9 ± 0.9 2.1 ± 1.3 NS
LH (IU/L) Day S8 1.9 ± 1.25 1.8 ± 0.95 NS
LH (IU/L) Day OPU 0.1 ± 0.1 0.1 ± 0.7 NS
Cumulative FSH dose (IU) 1959.8 ± 736.45 2435.9 ± 932.8 0.048
N. mature oocytes retrieved* 8.6 ± 4.9 7.3 ± 4.85 NS
N. embryos transferred* 1.6 ± 0.8 1.3 ± 0.6 0.042
Fertilization rate (%) 52 46 NS
Positive betahCG (%) 37 45 NS
Values are expressed as mean ± SD.
Abbreviations: NS not statistically significant; oPu ovum pick up.
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diol and LH levels throughout COS and in the mean
number of oocytes retrieved were observed between
groups. Fertilization rates and pregnancy rates per cycle
were also comparable. In contrast, the mean number ofFigure 1 Association between v-betaLH and different profiles of ovar
heterozygosis (n = 21); LH wild type (n = 196). r-hFSH: recombinant human
beta subunit luteinizing hormone.embryos transferred was significantly lower in group B
compared to Group A (1.3 ± 0.6 versus1.6 ± 0.8, p = 0.042)
(Table 3). Moreover, Group B received a marginal but sta-
tistically higher cumulative-dose of r-hFSH (1959.8 ±
736.45 versus 2435.86 ± 932.8 IU, p = 0.048) (Table 3).
When one-way ANOVA in a within design was applied,
the LH genotype (factor) had a statistically significant ef-
fect (p <0.01) on the cumulative dose of r-hFSH, which
showed a progressive increase from wt/wt (1959.8 ±
736.45 IU) to v-betaLH hetero- (2267.5 ± 824.3) and
homozygotic women (3558.3 ± 970.9) (Figure 1). More-
over, the androstenedione serum concentration on the day
of triggering final oocyte maturation was statistically dif-
ferent between groups A and B (1.49 ± 0.76 versus 2.06 ±
1.28, p = 0.02). This difference disappeared on the day of
oocyte retrieval (Table 3).
Population has been also stratified in quartiles group
according r-hFSH consumption (Figure 2). The allelic
frequency of v-betaLH was progressively 12.5%, 12.5%,
33.5% and 41.5% from the first to the fourth quartile.
When a ROC curve was calculated (Area under the
curve value, AUC 0.676), a cumulative dose of r-hFSH
of 1862.5 IU was identified as the most predictive cut-off
for the presence of the LH variant (Sensitivity: 0.75 – 1 -
Specificity: 0.44) (Figure 3). The study population was
stratified into two subgroups on the basis of this cut-off
value. Group 1 included 115 women who received a cu-
mulative dose of r-hFSH ≤1862.5 IU; group 2 includedian response to r-hFSH. v-betaLH homozygosis (n = 3); v-betaLH
follicle-stimulating hormone; LH luteinizing hormone; v-betaLH: variant
Figure 2 Population stratified according by quartiles of cumulative r-hFSH dose. 1st quartile; 2nd quartile; 3rd quartile; 4th quartile. r-hFSH:
recombinant human follicle-stimulating hormone; LH luteinizing hormone; v-betaLH: variant beta subunit luteinizing hormone.
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Considering groups 1 and 2, respectively, no statistically
significant differences emerged in age (32.07 ± 3.85 versus
31.09 ± 3.74), BMI (24.01 ± 3.16 versus 23.9 ± 3.10 Kg/m2)
and basal FSH (6.7 ± 1.71 versus 6.56 ± 1.83 IU/L) were
similar between groups. When the LH genotype was eval-
uated, 6/115 (5.2%) and 18/105 (17.1%) carriers were
found in the two groups, respectively (p <0.005).
Discussion
This is the first study exploring the v-betaLH frequency
in a Danish IVF population. V-betaLH was present in
10.9% of patients, whereas the allelic frequency was
12.2%, quite similar to that reported for a number of
other European populations, however somewhat lower
than that of the Finnish population [17].
The study confirms data reported in a previous paper
[7], demonstrating that v-betaLH is associated with a
higher consumption of r-hFSH during COS. Morespecifically, a relationship between the r-hFSH cumula-
tive dose and the LH genotype was found, where the go-
nadotropin cumulative dose showed a positive trend in
v-betaLH women. Although only three women with the
variant in homozygosis were analyzed, it is interesting to
remark that a sort of gradient in r-hFSH consumption
was observed, with the lowest in the wt/wt group and
the highest in v-betaLH homozygotic carriers (Figure 1).
The mean number of oocytes retrieved was not related
to the LH genotype (Table 3). This parameter was pre-
ferred to the number of dominant follicles as indicator
of ovarian response. This choice was related to the fact
that evaluation of dominant follicles, usually performed
by different physicians, is more subjective, mainly when
ovaries are “crowded”. In contrast, ovum pick up is a
more standardized procedure which was performed by
the same operator in all cases (P.H.). A cumulative dose
of r-hFSH 1862.5 IU was identified as the most pre-
dictive cut-off for the presence of LH variant. Taken
Figure 3 ROC curve dependent variable cumulative dosage of FSH and independent v-betaLH expression. Red dart shows the most
predictive cut-off. Cumulative dosage r-hFSH (UI) cut-off 1862.5 IU. Sensitivity: 0.750; 1-Specificity: 0.444.
Alviggi et al. Reproductive Biology and Endocrinology 2013, 11:51 Page 6 of 8
http://www.rbej.com/content/11/1/51together, these data raise the question of whether
v-betaLH assessment of all patients should be employed
prior to ovarian stimulation, or whether one should
await the results of the first stimulated cycle. Following
this line, a good prognosis patient who, despite a starting
dose of 150 IU of r-hFSH needed a cumulative dose
higher than 2000 IU to achieve an apparently normal
response (i.e. at least 5 oocytes retrieved) should be
recommended for LH genotyping. If the patient was
either homo-or heterozygotic for v-betaLH, the recom-
mendation would be to add exogenous LH rather than
increase the FSH dose during the subsequent cycle [2-4].
In the present study, serum samples from a previous
study [13] were analyzed, which in turn made not pos-
sible the use of molecular biology approach (i.e., poly-
merase chain reaction). Nevertheless, the immuno-assay
adopted is a well established method which has been
validated in previous studies [16].
Wild-type and v-betaLH hormones are functionally dif-
ferent. More specifically, v-betaLH seems to possess a
shorter half-life, however, with a more potent action at the
receptor level when compared to the wild-type [12,18].
Thus, it is expected that the phenotypic expression of the
hormone types may be different. Also the combination of
the two forms of LH, i.e. heterozygous for wild-type and
v-betaLH, could differ from both of the wt and v-betaLH
homozygous phenotypes. Furthermore, a number of dif-
ferent LH-receptors genotypes exist and whether theinteraction between the subtypes of LH and the different
subtypes of the LH-receptor is unequal is currently un-
known. Due to the low frequency of the v-betaLH homo-
zygotes, no clear picture of the phenotypic effects of the
variant has yet emerged. Several authors ascribe a higher
activity to the variant LH due to elevated levels of serum
estradiol, testosterone and sex hormone-binding globulin
compared to wild-type LH women [19]. On the other
hand, there is evidence that v-betaLH protects obese
women from developing symptomatic polycystic ovarian
syndrome [20]. Moreover, observational trials suggest that
v-betaLH is related to a reduced gonadal function and
subfertility [21]. Finally, differences in the circulatory kin-
etics between the two types of LH may explain the diver-
sities in LH function between patients with ovulatory
disorders and women with normal ovulatory cycles [22].
This study confirms that v-betaLH carriers need a higher
FSH dose during COS, supporting the idea that this poly-
morphism represents a biologically less active form of LH,
unable to adequately support FSH activity during follicular
stimulation. In this series of patients no difference in
terms of fertilization and pregnancy rates were found
between groups, indicating that increasing r-hFSH dose
during COS may counteract lower v-betaLH activity.
Nevertheless, women with v-betaLH showed a statistically
significant reduction in the mean number of embryos
transferred (Table 3). This observation may be consistent
with the evidence that cooperation between FSH and LH
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maturation, including resumption of oocyte meiosis
[23-25]. Taken together, these aspects raise the question
whether the use of higher doses of r-hFSH is able to to-
tally overcome the impact of the LH variant on oocyte
competence and on the outcome of IVF. This point could
be addressed by further investigation in a larger study
population. On the other hand, it could be argued that
exogenous LH supplementation in v-betaLH carriers is
capable of correcting ovarian response to FSH. This hy-
pothesis is consistent with studies demonstrating that
young, normogonadotrophic women showing slower and
suboptimal response to exogenous r-hFSH benefit from
r-hLH supplementation [2-4].
Interestingly, the serum androstenedione level on the
day of triggering final oocyte maturation was signifi-
cantly elevated in patients with v-betaLH. A previous
study found that women following a standard long
GnRH-agonist protocol stimulated with r-hFSH showed
a significant positive association between serum levels of
LH and androstenedione on day 8 of stimulation [26],
supporting that LH has a pronounced effect on the circu-
latory concentration of androstenedione. This paradox
may be related with the augmented FSH consumption in
the v-betaLH group. In fact, FSH may via the granulosa
cells increase the capacity of the theca cell compartment
to produce androgens by stimulating the expression of
Cytochrome P450 17alpha-hydroxylase (CYP17). This hy-
pothesis is consistent with evidence from rats model [27].Conclusions
In conclusion, the present results provide, for the first
time, information on the v-betaLH frequency in a Danish
IVF population, confirming that carriers of the poly-
morphism require higher doses of r-hFSH during COS.
The evidence supports the idea that v-betaLH represents
a less bioactive variant of LH. Furthermore, on our way to
an individualized-pharmacogenomic approach to COS, we
suggest that LH genotyping provides important informa-
tion for the clinician prior to ovarian stimulation.
On the bases of these results, it could be interesting to
test the hypothesis that LH supplementation is able to
improve both ovarian response and outcome of IVF in
v-betaLH carriers. An adequate sample size should be
calculated in a future RCT having v-betaLH carriers
treated with only FSH as control group.
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